Prevention of Alcohol and Drug Abuse Sample Clauses

Prevention of Alcohol and Drug Abuse. The department commits to; a) Conduct a baseline survey on alcohol and drug abuse(50%) b) Sensitize staff on alcohol and Drug abuse(25%) c) Undertake counselling, treatment and rehabilitation of staff suffering from alcohol and drug addiction(15%) d) A strategic placed inscribed sign board ( NO SMOKING ZONE/UVUTAJI WA SIGARA HAURUHUSIWI HAPA) will be available in the departmental offices (10%)
Sample 1
AutoNDA by SimpleDocs
Prevention of Alcohol and Drug Abuse. (10%) The department aims at reducing alcohol and drug abuse (ADA) among the staff in the department by carrying out the following: i) Participate in County Baseline Survey on alcohol and substance abuse to be spearheaded by the department of DPSDM and implement the recommendations (30%). ii) The Department will undertake the following interventions towards prevention of alcohol and substance abuse: a. Domesticate and implement the workplace policy on ASA developed department of DPSDM (15%). b. Nominate staff to be an ASA committee (5%) c. Sensitization of Staff on alcohol and substance abuse (15%)
Sample 1
Prevention of Alcohol and Drug Abuse. The department commits to 1. To do a 1No. Sensitization/ awareness meeting on drug abuse for the staff and contractors during site meetings. (40%) 2. Provide information on available counselling centers. (20%) 3. Distribute Fliers on management of alcohol and drug abuse. (40%) 2 Prevention of HIV Infections The department commits to: 1. Hold 1No. Sensitization/ awareness meeting on HIV aids for the staff and contractors’ workers during site meetings (40%) 2. Display HIV/AIDS awareness messages on all our projects publicity signboards. (50%) 3. Provide information on available counselling centers. (10%) 3 Disability Mainstreaming The department commits to: Sensitize construction contractors to provide work opportunities to PLWDs. (100%) Criteria Category Notes
Sample 1
Prevention of Alcohol and Drug Abuse. The Department commits to; i) Sensitize staff on alcohol and drug abuse -40% ii) Recommend cases of rehabilitation, treatment and counselling for staff-40% iii) Follow up rehabilitated cases-20%
Sample 1
Prevention of Alcohol and Drug Abuse. Towards prevention of Alcohol and Drug Abuse, the Council will carry out the following;
Sample 1
Prevention of Alcohol and Drug Abuse. During this contract period the council shall:- • Form a committee • Develop and implement workplace policy on alcohol and drug abuse • Establish alcohol and drug abuse prevention unit • Implement the alcohol and drug abuse
Sample 1

Related to Prevention of Alcohol and Drug Abuse

  • Alcohol and Drug Testing Employee agrees to comply with and submit to any Company program or policy for testing for alcohol abuse or use of drugs and, in the absence of such a program or policy, to submit to such testing as may be required by Company and administered in accordance with applicable law and regulations.

  • Alcohol and Drugs Service Provider agrees that the presence of alcohol and drugs are prohibited on the Work Site and while performing their Services. If the Service Provider or any of their agents, employees, or subcontractors are determined to be present or with alcohol or drugs in their possession, this Agreement shall terminate immediately.

  • DRUG/ALCOHOL TESTING 11.1 The parties agree that the maintenance of a drug/alcohol free work place is a goal of both the College and the Union. Employees are prohibited from possession, consumption and/or being under the influence of a controlled substance/alcohol while on the College’s premises or during time paid by the employer. Violations of this prohibition may result in a disciplinary action up to and including termination.

  • FDA As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a “Pharmaceutical Product”), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.

  • DRUG AND ALCOHOL TESTING Employees may be tested for drugs and/or alcohol pursuant to the provisions of the Employer's Drug and Alcohol Testing Policy which is attached hereto and made a part of this Agreement as if more fully set forth herein.

  • Fraud, Waste, and Abuse Contractor understands that HHS does not tolerate any type of fraud, waste, or abuse. Violations of law, agency policies, or standards of ethical conduct will be investigated, and appropriate actions will be taken. Pursuant to Texas Government Code, Section 321.022, if the administrative head of a department or entity that is subject to audit by the state auditor has reasonable cause to believe that money received from the state by the department or entity or by a client or contractor of the department or entity may have been lost, misappropriated, or misused, or that other fraudulent or unlawful conduct has occurred in relation to the operation of the department or entity, the administrative head shall report the reason and basis for the belief to the Texas State Auditor’s Office (SAO). All employees or contractors who have reasonable cause to believe that fraud, waste, or abuse has occurred (including misconduct by any HHS employee, Grantee officer, agent, employee, or subcontractor that would constitute fraud, waste, or abuse) are required to immediately report the questioned activity to the Health and Human Services Commission's Office of Inspector General. Contractor agrees to comply with all applicable laws, rules, regulations, and System Agency policies regarding fraud, waste, and abuse including, but not limited to, HHS Circular C-027. A report to the SAO must be made through one of the following avenues: ● SAO Toll Free Hotline: 1-800-TX-AUDIT ● SAO website: xxxx://xxx.xxxxx.xxxxx.xx.xx/ All reports made to the OIG must be made through one of the following avenues: ● OIG Toll Free Hotline 0-000-000-0000 ● OIG Website: XxxxxxXxxxxXxxxx.xxx ● Internal Affairs Email: XxxxxxxxXxxxxxxXxxxxxxx@xxxx.xxxxx.xx.xx ● OIG Hotline Email: XXXXxxxxXxxxxxx@xxxx.xxxxx.xx.xx. ● OIG Mailing Address: Office of Inspector General Attn: Fraud Hotline MC 1300 P.O. Box 85200 Austin, Texas 78708-5200

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • Occupational Health and Safety Act The Employer, the Union and the employees agree to be bound by the provisions of the Occupational Health and Safety Act, S.N.S. 1996, c.7.

  • DRUG AND ALCOHOL FREE WORKPLACE 22.1 All employees must report to work in a condition fit to perform their assigned duties unimpaired by alcohol or drugs. Each institution is required to comply with the Drug-Free Schools and Communities Act (DFSCA) and the Drug-Free Schools and Campuses Regulations in order to be eligible for federal funding.

Time is Money Join Law Insider Premium to draft better contracts faster.